Marienhospital Bottrop

Mutations in BRCA1/2 and Other Panel Genes in Patients With Metastatic Breast Cancer -Association With Patient and Disease Characteristics and Effect on Prognosis (2021) Fasching P, Yadav S, Hu C, Wunderle M, Häberle L, Hart SN, Rübner M, et al. Journal article Update Breast Cancer 2021 Part 2-Advanced Stages, Long-Term Consequences and Biomarkers (2021) Ditsch N, Stickeler E, Behrens A, Belleville E, Fasching P, Fehm TN, Hartkopf AD, et al. Journal article, Review article Update Breast Cancer 2021 Part 1-Prevention and Early Stages (2021) Stickeler E, Aktas B, Behrens A, Belleville E, Ditsch N, Fasching P, Fehm TN, et al. Journal article, Review article Update Breast Cancer 2020 Part 5 - Moving Therapies from Advanced to Early Breast Cancer Patients (2021) Lux MP, Schneeweiss A, Hartkopf AD, Müller V, Janni W, Belleville E, Stickeler E, et al. Journal article, Review article Challenges and Opportunities for Real-World Evidence in Metastatic Luminal Breast Cancer (2021) Lüftner D, Hartkopf AD, Lux MP, Overkamp F, Tesch H, Titzmann A, Pöschke P, et al. Journal article, Review article Corrigendum to “Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany” (The Breast (2020) 54 (88–95), (S0960977620301648), (10.1016/j.breast.2020.08.011)) (2021) Schneeweiss A, Ettl J, Lüftner D, Beckmann M, Belleville E, Fasching P, Fehm TN, et al. Journal article, Erratum Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany (2020) Hübner H, Kurbacher CM, Kuesters G, Hartkopf AD, Lux MP, Huober J, Volz B, et al. Journal article Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany (2020) Schneeweiss A, Ettl J, Lüftner D, Beckmann M, Belleville E, Fasching P, Fehm TN, et al. Journal article Update Breast Cancer 2020 Part 3 - Early Breast Cancer (2020) Huober J, Schneeweiss A, Hartkopf AD, Müller V, Lux MP, Janni W, Ettl J, et al. Journal article, Review article Treatment landscape and prognosis after treatment with trastuzumab emtansine (2020) Laakmann E, Emons J, Taran FA, Janni W, Uhrig S, Overkamp F, Kolberg HC, et al. Journal article